JP2016525139A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525139A5
JP2016525139A5 JP2016528526A JP2016528526A JP2016525139A5 JP 2016525139 A5 JP2016525139 A5 JP 2016525139A5 JP 2016528526 A JP2016528526 A JP 2016528526A JP 2016528526 A JP2016528526 A JP 2016528526A JP 2016525139 A5 JP2016525139 A5 JP 2016525139A5
Authority
JP
Japan
Prior art keywords
protein
antigen
antibody
composition according
binding polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528526A
Other languages
English (en)
Other versions
JP6503349B2 (ja
JP2016525139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065840 external-priority patent/WO2015011199A1/en
Publication of JP2016525139A publication Critical patent/JP2016525139A/ja
Publication of JP2016525139A5 publication Critical patent/JP2016525139A5/ja
Application granted granted Critical
Publication of JP6503349B2 publication Critical patent/JP6503349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. モノクローナル抗体、ポリクローナル抗体、抗体断片、抗体断片を含む融合タンパク質、抗体薬物複合体またはこれらの任意の組み合わせから選択される抗原結合ポリペプチドまたはタンパク質と、液体ビヒクルとを含み、前記液体ビヒクルが式
    RFRH
    (式中、RFは4から12の炭素原子を有する線形過フッ素化炭水化物セグメントであり、RHは4から8の炭素原子を有する線形アルキル基である)の半フッ素化アルカンを含み、前記抗原結合ポリペプチドまたはタンパク質が、分散液または懸濁液を形成するように組み込まれる組成物であって、その初期の抗原結合活性の少なくとも85%を、RTから40℃の間の温度において6ヶ月の保存の間保持する、組成物。
  2. 前記抗体断片が、抗原結合断片(Fab)、単鎖可変断片(scFv)、単一ドメイン抗体、ミニボディまたはダイアボディである、請求項に記載の組成物。
  3. 前記モノクローナル抗体がキメラ、ヒト化またはヒト抗体である、請求項に記載の組成物。
  4. 前記抗原結合ポリペプチドまたはタンパク質が、少なくとも90kDaの分子量を有する、請求項1からのいずれかに記載の組成物。
  5. 前記半フッ素化アルカンが、F4H5、F4H6、F4H8、F6H4、F6H6、F6H8およびF6H10から選択される、請求項1からのいずれかに記載の組成物。
  6. 有効に水を含まない、請求項1からのいずれかに記載の組成物。
  7. 前記抗原結合ポリペプチドまたはタンパク質が少なくとも0.5mg/mLの濃度である、請求項1からのいずれかに記載の組成物。
  8. 医薬品としての使用のための、請求項1からのいずれかに記載の組成物。
  9. 皮下、経皮、筋肉内または局所領域注射による非経口投与用の医薬品としての使用のための、請求項に記載の組成物。
  10. 抗原結合ポリペプチドまたはタンパク質と、式
    RFRH
    (式中、RFは4から12の炭素原子を有する線形過フッ素化炭水化物セグメントであり、RHは4から8の炭素原子を有する線形アルキル基である)の半フッ素化アルカンを含む液体ビヒクルとを、懸濁液または分散液を形成するように混合するステップを含む、抗原結合ポリペプチドまたはタンパク質を安定化させる方法であって、
    前記抗原結合ポリペプチドまたはタンパク質がモノクローナル抗体、ポリクローナル抗体、抗体断片、抗体断片を含む融合タンパク質、抗体薬物複合体またはこれらの任意の組み合わせから選択される、方法
  11. 前記抗原結合ポリペプチドまたはタンパク質が、初期の抗原結合活性の少なくとも85%を、RTから40℃の間の温度において6ヶ月の保存の間保持する、請求項10に記載の方法。
  12. がんまたは自己免疫疾患の治療用の医薬品としての使用のための、請求項に記載の組成物。
  13. 前記抗原結合ポリペプチドまたはタンパク質が、血管新生阻害剤、抗増殖剤またはTNF阻害剤である、請求項に記載の組成物。
JP2016528526A 2013-07-23 2014-07-23 安定化された抗体組成物 Active JP6503349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13177699.9 2013-07-23
EP13177699 2013-07-23
PCT/EP2014/065840 WO2015011199A1 (en) 2013-07-23 2014-07-23 Stabilized antibody compositions

Publications (3)

Publication Number Publication Date
JP2016525139A JP2016525139A (ja) 2016-08-22
JP2016525139A5 true JP2016525139A5 (ja) 2017-08-24
JP6503349B2 JP6503349B2 (ja) 2019-04-17

Family

ID=48803483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528526A Active JP6503349B2 (ja) 2013-07-23 2014-07-23 安定化された抗体組成物

Country Status (15)

Country Link
US (3) US10273298B2 (ja)
EP (1) EP3024484B1 (ja)
JP (1) JP6503349B2 (ja)
KR (1) KR102272568B1 (ja)
CN (2) CN105555311B (ja)
AU (1) AU2014295052B2 (ja)
BR (1) BR112016001522B1 (ja)
CA (1) CA2918419C (ja)
DK (1) DK3024484T3 (ja)
ES (1) ES2687094T3 (ja)
HK (1) HK1224218A1 (ja)
MX (1) MX370207B (ja)
PL (1) PL3024484T3 (ja)
PT (1) PT3024484T (ja)
WO (1) WO2015011199A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103596554A (zh) 2011-05-25 2014-02-19 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
CN106511322B (zh) 2012-09-12 2021-09-17 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
MX370207B (es) 2013-07-23 2019-12-05 Novaliq Gmbh Composiciones estabilizadas de anticuerpos.
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
PL3355990T3 (pl) 2015-09-30 2019-11-29 Novaliq Gmbh Semifluorowane związki oraz ich kompozycje
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
JP2019520357A (ja) * 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
PL3856128T3 (pl) 2018-09-27 2023-10-16 Dermaliq Therapeutics, Inc. Formulacja filtra przeciwsłonecznego do stosowania miejscowego
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220143137A1 (en) 2019-02-13 2022-05-12 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CN115151242A (zh) 2019-11-27 2022-10-04 诺瓦利克有限责任公司 包含悬浮在非水性媒介物中的蛋白质颗粒的悬浮液

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
IN184589B (ja) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
EP0983037B1 (en) 1998-02-09 2003-05-02 MacroChem Corporation Antifungal nail lacquer
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
IL141095A0 (en) 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
IL144755A0 (en) 1999-02-08 2002-06-30 Alza Corp Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
ES2299630T3 (es) 2001-09-04 2008-06-01 TROMMSDORFF GMBH & CO.KG ARZNEIMITTEL Emplastos para la profilaxis y/o el tratamiento de disfunciones o trastornos del crecimiento de las uñas.
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2422768B1 (en) 2003-08-25 2015-04-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
CA2540621A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1740189B1 (en) 2004-04-19 2012-06-13 Centre National De La Recherche Scientifique -Cnrs- Lung surfactant supplements
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
RU2007103835A (ru) 2004-07-01 2008-08-10 Шепенс Ай Рисерч (Us) Композиции и способы лечения заболеваний и нарушений состояния глаз
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
ATE420625T1 (de) 2005-08-05 2009-01-15 Bharat Serums & Vaccines Ltd Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したvegfアンタゴニスト製剤
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス,インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
JP5569899B2 (ja) 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
US20100000899A1 (en) * 2008-07-07 2010-01-07 Panasonic Corporation Medication blister pack with embedded user interface
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス,インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法
PL2387391T3 (pl) 2009-07-24 2017-09-29 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2792517C (en) * 2010-03-09 2020-03-24 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2661280T3 (en) 2011-01-04 2019-03-04 Novaliq Gmbh O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES
WO2012142670A1 (en) * 2011-04-20 2012-10-26 The University Of Queensland Nuclear magnetic resonance agent
CN103596554A (zh) 2011-05-25 2014-02-19 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
CA2873646C (en) 2012-05-18 2022-04-26 Genentech, Inc. High-concentration monoclonal antibody formulations
CN106511322B (zh) 2012-09-12 2021-09-17 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
CA2891686A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
MX370207B (es) 2013-07-23 2019-12-05 Novaliq Gmbh Composiciones estabilizadas de anticuerpos.
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
PL3355990T3 (pl) 2015-09-30 2019-11-29 Novaliq Gmbh Semifluorowane związki oraz ich kompozycje
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
BR112018013805A2 (pt) 2016-01-08 2018-12-11 Clearside Biomedical, Inc. métodos e dispositivos para o tratamento de distúrbio ocular posterior com aflibercept e outros produtos biológicos
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
KR20190060787A (ko) 2016-09-28 2019-06-03 노바리크 게엠베하 카나비노이드 수용체 결합 리간드를 포함하는 조성물
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
US20190328717A1 (en) 2016-12-22 2019-10-31 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
MX2019007587A (es) 2016-12-23 2019-12-16 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
US20220143137A1 (en) 2019-02-13 2022-05-12 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CN115151242A (zh) 2019-11-27 2022-10-04 诺瓦利克有限责任公司 包含悬浮在非水性媒介物中的蛋白质颗粒的悬浮液

Similar Documents

Publication Publication Date Title
JP2016525139A5 (ja)
JP2019110906A5 (ja)
JP2018527919A5 (ja)
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
JP2014158469A5 (ja)
JP2017506217A5 (ja)
JP2018500014A5 (ja)
JP2019516394A5 (ja)
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
JP2019513777A5 (ja)
JP2019510733A5 (ja)
JP2017535257A5 (ja)
PH12019501014A1 (en) Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
JP2017531427A5 (ja)
JP2018502060A5 (ja)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2015535691A5 (ja)
JP2018521691A5 (ja)
JP2014221758A5 (ja)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2014509510A5 (ja)
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
PE20190920A1 (es) Anticuerpos modificados de union a fcrn humano y metodos de utilizacion